NL-OMON45060
Completed
Not Applicable
Post-operative RadioTherapy for patients with metastases of the long bones - OPTIMAL-PORT Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- metastatic bone disease
- Sponsor
- eids Universitair Medisch Centrum
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Aged 18 or older
- •\- Receive surgical treatment (prosthesis, intramedullary nail, plate, curettage with/without cement) with palliative intent for a pathologic fracture or impending pathologic fracture of the extremities (humerus/femur and further distal) due to metastatic bone disease
- •\- Radiographic or histologic proof of metastatic bone disease
- •\- Histologic diagnosis of the primary tumour or \* if the diagnosis is unknown \- at least adequate diagnostic investigations into the origin of the metastasis (e.g. dissemination imaging, histology, biopsy)
Exclusion Criteria
- •\- Communication with patient is hampered (e.g. language barrier, severe cognitive impairment, dementia)
- •\- The treated lesion originates from multiple myeloma, solitary plasmacytoma or lymphoma of bone
- •\- Further radiotherapy is considered inappropriate (\> 2 series RT on current lesion)
- •\- Physically unable to undergo post\-operative RT treatment, according to treating doctor\*s opinion
- •\- Absolute need for post\-operative treatment with radiotherapy, specify reason:
- •o Extent of bone lesion (outside surgical field)
- •o Soft tissue involvement
- •o Curative intent of treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Postoperative radiotherapy (PORT) for pathological N2 non-small cell lung cancer with adjuvant chemotherapy: a randomized phase III trial (JCOG1916, J-PORT)pathological N2 non-small cell lung cancerJPRN-UMIN000042905Japan Clinical Oncology Group (JCOG)330
Completed
Phase 4
Effectiveness of postoperative radiotherapy in patients with oral or oropharyngeal squamous cell carcinoma and histologically confirmed single ipsilateral lymphnode metastasis (pN1)head-neck cancer metastasisoral cancer1002747610019190NL-OMON30589Academisch Medisch Centrum12
Active, not recruiting
Phase 1
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A Phase III studyEUCTR2006-002772-17-FREuropean Organisation for Research and Treatment of Cancer86
Completed
Not Applicable
Post-Operative Radiotherapy for Selected High Risk Rectal AdenocarcinomaColorectal cancerCancerColorectalISRCTN91411631orthern and Yorkshire Clinical Trials and Research Unit (UK)
Active, not recruiting
Not Applicable
Radioterapia externa postoperatoria combinada con tratamiento hormonal adyuvante y concomitante frente a la radioterapia externa postoperatoria como tratamiento único en el carcinoma de próstata estadio pT3a-b R0-1 N0M0 / pT2R1 N0M0 y con puntuación de Gleason 5-10. Estudio fase III.(Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A Phase III study)n carcinoma de próstata estadio pT3a-b R0-1 N0M0 / pT2R1 N0M0 y con puntuación de Gleason 5-10.(Prostatic carcinoma with pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10)MedDRA version: 9.1Level: LLTClassification code 10036955Term: Prostatic carcinomaEUCTR2006-002772-17-ESEuropean Organisation for Research and Treatment of Cancer600